About
Apexigen is a clinical-stage biopharmaceutical company discovering and developing the next generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products that harness the patient’s immune system to combat and eradicate cancer.
Immuno-oncology
Recent advances in cancer immunology have increased our understanding of the mechanisms that cancer cells use to either avoid detection by or to de-activate the immune system. Novel immuno-oncology drugs are designed specifically to block immune suppression induced by tumors, or to actively initiate and augment an immune response against tumors. Manipulating the body’s immune system can lead to elimination of tumors and prevention of tumor recurrence (for a long-lasting cure).
Apexigen’s Immuno-oncology Strategy
Apexigen is focused on discovering and developing innovative drugs that enhance tumor-specific immunity. The use of its APXiMAB™ platform enables Apexigen to discover antibodies with unique attributes against known and novel immune system targets. These antibodies have demonstrated the potential to become the next generation of cancer therapies as we progress toward the ultimate cure for cancer.
News
December 6, 2019
Apexigen Expands Leadership Team with Two Key Appointments
in CMC and Clinical Development
October 16, 2019
Apexigen’s CEO, Xiaodong Yang, Recognized Among 100
Most Intriguing Entrepreneurs at Goldman Sachs 2019 Builders + Innovators Summit
October 16, 2019
Apexigen to Present at the 2019 Solebury Trout Private Company
Showcase
October 9, 2019
Apexigen Appoints Biotechnology Financial Executive Herb
Cross to Board of Directors
Sept 24, 2019
Apexigen Announces Participation In Upcoming Oncology Conferences
Sept 4, 2019
Apexigen Appoints Scott Smith to Board of Directors
April 1, 2019
Apexigen Presents Clinical Data on CD40 Antibody APX005M
in Metastatic Melanoma at the AACR Annual Meeting 2019
March 31, 2019
Apexigen Announces New Clinical Data on APX005M in Combination
Therapy for Pancreatic Cancer at the AACR Annual Meeting 2019
March 20, 2019
Apexigen Announces Clinical Data Presentations on CD40 Antibody
APX005M at the AACR Annual Meeting 2019
February 19, 2019
Apexigen to present at upcoming Investor Conferences
